Christopher D. Maggiore Acquires 7,200 Shares of ZIVO Bioscience, Inc. (OTCMKTS:ZIVO) Stock

ZIVO Bioscience, Inc. (OTCMKTS:ZIVOGet Rating) Director Christopher D. Maggiore acquired 7,200 shares of the business’s stock in a transaction on Wednesday, September 14th. The stock was purchased at an average cost of $3.53 per share, with a total value of $25,416.00. Following the acquisition, the director now directly owns 810,305 shares of the company’s stock, valued at approximately $2,860,376.65. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

ZIVO Bioscience Stock Up 1.3 %

ZIVO opened at $3.18 on Wednesday. ZIVO Bioscience, Inc. has a fifty-two week low of $2.37 and a fifty-two week high of $6.98. The company has a fifty day moving average of $3.73 and a two-hundred day moving average of $3.58.

ZIVO Bioscience (OTCMKTS:ZIVOGet Rating) last released its quarterly earnings data on Thursday, August 4th. The biotechnology company reported ($0.22) earnings per share for the quarter.

Institutional Trading of ZIVO Bioscience

An institutional investor recently raised its position in ZIVO Bioscience stock. Vanguard Group Inc. grew its stake in ZIVO Bioscience, Inc. (OTCMKTS:ZIVOGet Rating) by 19.6% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 92,468 shares of the biotechnology company’s stock after purchasing an additional 15,147 shares during the quarter. Vanguard Group Inc. owned approximately 0.98% of ZIVO Bioscience worth $359,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 5.04% of the company’s stock.

ZIVO Bioscience Company Profile

(Get Rating)

ZIVO Bioscience, Inc, a research and development company, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food manufacturers. It operates in the biotech and agtech sectors, with an intellectual property portfolio comprising proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health.

Recommended Stories

Receive News & Ratings for ZIVO Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIVO Bioscience and related companies with's FREE daily email newsletter.